Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
17,88 USD | +1,53% | +5,74% | +1,94% |
23/04 | La perdita Q1 di Kiniksa Pharmaceuticals si allarga, ma le entrate aumentano | MT |
23/04 | Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024 |
Attività
Numero di dipendenti: 297
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Therapeutic Medicines
100,0
%
| 220 | 100,0 % | 270 | 100,0 % | +22,74% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Bermuda
100,0
%
| 220 | 100,0 % | 270 | 100,0 % | +22,74% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Eben Tessari
FOU | Founder | 42 | 01/07/15 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 01/07/15 |
Mark Ragosa
DFI | Director of Finance/CFO | 50 | 01/05/18 |
Chad Morin
CMP | Compliance Officer | - | 01/10/20 |
John Paolini
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/08/16 |
Rachel Frank
IRC | Investor Relations Contact | - | - |
General Counsel | - | 01/08/20 | |
Ross Moat
PRN | Corporate Officer/Principal | 43 | 01/01/19 |
Martina Struck
LAW | General Counsel | - | 01/01/18 |
Melissa Manno
HRO | Human Resources Officer | - | 01/01/17 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | 01/10/15 |
Barry D. Quart
BRD | Director/Board Member | 67 | 01/10/15 |
Thomas Malley
BRD | Director/Board Member | 55 | 01/12/16 |
Richard Levy
BRD | Director/Board Member | 66 | 04/03/19 |
Kim Popovits
BRD | Director/Board Member | 65 | 01/02/18 |
G. Cole
BRD | Director/Board Member | 68 | 27/07/20 |
Stephen Biggar
BRD | Director/Board Member | 53 | 01/10/15 |
Sanj Patel
CEO | Chief Executive Officer | 54 | 01/07/15 |
Tracey McCain
BRD | Director/Board Member | 56 | 01/02/18 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 16 057 618 | 0 | 0 | 54,58 % |
Azione B | 1 | 12 781 964 | 0 | 0 | |
Azione C | 1 | 1 795 158 | 0 | 0 | |
Azione D | 1 | 40 305 405 | 38 720 038 ( 96,07 %) | 0 |
Coordinate società
Settore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+1,94% | 1,27 Mrd | |
-2,31% | 103 Mrd | |
+0,56% | 95,28 Mrd | |
+1,69% | 22,15 Mrd | |
-17,37% | 21,02 Mrd | |
-9,30% | 18,15 Mrd | |
-41,01% | 16,73 Mrd | |
-14,85% | 16,05 Mrd | |
+3,21% | 13,68 Mrd | |
+33,54% | 12,17 Mrd |
- Borsa valori
- Azioni
- Azione KNSA
- Società Kiniksa Pharmaceuticals, Ltd.